Metastatic Breast Adenocarcinoma

Breast Cancer

400 mg, corresponding to two 4 g stick packs applications twice daily

CR1447

Kantonsspital Aarau

Kantonsspital Baden

Universitätsspital Basel

Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli

Oncocare / Klinik Engeried

Inselspital Bern

Kantonsspital Graubünden

Kantonsspital Frauenfeld / Brustzentrum Thurgau

Luzerner Kantonsspital

Kantonsspital St. Gallen

Spital STS AG

Kantonsspital Winterthur

Onkozentrum - Klinik im Park

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer

DC24 is obtained in a patient who achieves complete response (CR) or partial response (PR) within the first 24 ± 2 weeks of treatment or stable disease (SD) for at least 24 weeks after treatment start according to the RECIST 1.1 criteria.
For patients without CR or PR and no PD before 24 weeks:
If the tumor assessment at 24 ± 2 weeks is missing but a later assessment shows SD, the patient will be counted as obtaining DC24.
If the tumor assessment at 24 ± 2 weeks is missing and there are no further tumor assessments or the subsequent assessment shows PD, the patient will be counted as not obtaining DC24.
Tumor assessments showing CR or PR have to be confirmed after 4 weeks.

Swiss Group for Clinical Cancer Research

virilism

süd vəzi xərçəngi

breast neoplasms

virilism/süd vəzi xərçəngi

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası